A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer

Investigational New Drugs

Volumn 33, Issue 1, 2015, Pages 187-193

  Bendell, Johanna C ^a,b   Jones, Suzanne F ^a   Hart, Lowell ^a,c   Spigel, David R ^a,b   Lane, Cassie M ^a   Earwood, Chris ^a   Infante, Jeffrey R ^a,b   Barton, John ^a,b   Burris, Howard A ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Florida Cancer Specialists   (United States)

Author keywords

Everolimus; Linsitinib; Metastatic colorectal cancer; OSI 906

Indexed keywords

EVEROLIMUS; LINSITINIB; 3-(8-AMINO-1-(2-PHENYLQUINOLIN-7-YL)IMIDAZO(1,5-A)PYRAZIN-3-YL)-1-METHYLCYCLOBUTANOL; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRAZINE DERIVATIVE; RAPAMYCIN; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BLOOD TOXICITY; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; COUGHING; DEHYDRATION; DESQUAMATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DYSPNEA; DYSURIA; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; FATIGUE; FEMALE; FUNCTIONAL STATUS ASSESSMENT; HEMOPTYSIS; HUMAN; MALE; MAXIMUM TOLERATED DOSE; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RESPIRATORY FAILURE; SIDE EFFECT; SINUS CONGESTION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COLORECTAL NEOPLASMS; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMIDAZOLES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRAZINES; RECEPTOR, IGF TYPE 1; SIROLIMUS;

EID: 84922092092     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0177-3     Document Type: Article

References (26)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA: A Cancer Journal for Clinicians 62:10-29
2. Van Cutsem E, Peeters M, Siena S et al (2007) Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. J Clin Oncol 25:1658-1664
3. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase-AKT pathway in human cancer. Nat Rev Cancer 2:489-501
4. Altomare I, Bendell JC, Bullock KE et al (2011) A Phase II Trial of Bevacizumab plus Everolimus for Patients with Refractory Metastatic Colorectal Cancer. The Oncologist 16:1131-1137
5. Evans T, Lindsay CR, Chan E et al (2010) Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors. ASCO Meeting Abstracts 28:2531
6. Baserga R (1999) The IGF-I Receptor in Cancer Research. Experimental Cell Research 253:1-6
7. Baserga R, Peruzzi F, Reiss K (2003) The IGF-1 receptor in cancer biology. International Journal of Cancer 107:873-877
8. Kurmasheva RT, Houghton PJ (2006) IGF-I mediated survival pathways in normal and malignant cells. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1766:1-22
9. Tao Y, Pinzi V, Bourhis J, Deutsch E (2007) Mechanisms of Disease: signaling of the insulin-like growth factor 1 receptor pathway [mdash]therapeutic perspectives in cancer. Nat Clin Prac Oncol 4:591-602
10. Baserga R (2005) The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opinion on Therapeutic Targets 9:753-768
11. O'Reilly KE, Rojo F, She Q-B et al (2006) mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt. Cancer Research 66:1500-1508
12. Wan X, Harkavy B, Shen N et al (2006) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26:1932-1940
13. Declaration of Helsinki. In. www.wma.net/e/ethicsunit/helsinki.htm: World Medical Association, Ethics Unit 2007.
14. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer 45:228-247
15. Storer BE (1989) Design and analysis of phase I clinical trials. Biometrics 45:925-937
16. NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4. In. http://evs.nci.gov/ftp1/CTCAE/about/html: National Cancer Institute 2010.
17. Fuchs CS, Tabernero JM, Hwang J et al. Multicenter phase II study of RAD001 in patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). 2009 Gastrointestinal Cancers Symposium 2009; Abstr #446.
18. Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520-529
19. Wolpin BM, Wei EK, Ng K et al (2008) Prediagnostic Plasma Folate and the Risk of Death in Patients With Colorectal Cancer. Journal of Clinical Oncology 26:3222-3228
20. Watkins DJ, Tabernero J, Schmoll H et al (2011) A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status. ASCO Meeting Abstracts 29:3501
21. Sathyanarayanan S, Ayers M, Cunningham D et al (2012) Activity of the anti-IGF-1R antibody dalotuzumab (MK-0646) in KRAS-mutant colorectal cancer: Preclinical and clinical data. ASCO Meeting Abstracts 30:3587
22. Eng C, Van Cutsem E, Nowara E et al (2011) A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses. ASCO Meeting Abstracts 29:3500
23. Sun S-Y, Rosenberg LM, Wang X et al (2005) Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition. Cancer Research 65:7052-7058
24. Tamburini J, Chapuis N, Bardet V et al (2008) Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 111:379-382
25. Quek R, Wang Q, Morgan JA et al (2011) Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 17:871-879
26. Di Cosimo S, Bendell JC, Cervantes-Ruiperez A et al (2010) A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. ASCO Meeting Abstracts 28:3008